Following global safety concerns, the National Agency for Food and Drug Administration and Control (NAFDAC), yesterday, said it will start investigating and responding to news of the recall of Indomie noodles by Taiwanese and Malaysian authorities.

The Applied Nutrition and Food Safety Directorate of NAFDAC will randomly sample Indomie noodles (including the seasoning) tomorrow (today), May 2, 2023, according to Director General Prof. Mojisola Adeyeye. Ethylene oxide is the substance that interests us.  There has been involvement from the Director of Food Lab Services. He is currently preparing the analysis’s methodology.

“It should be mentioned that the importation of Indomie noodles has long been prohibited.”  On the government’s list of foods that are prohibited, it is one of them. Nigerian law prohibits it, so NAFDAC does not recognize it. What we are doing is exercising extra caution to ensure that the product is not smuggled in, and if so, our post-marketing surveillance would detect it.

“We also want to be sure that the spices used for Indomie and other noodles in Nigeria are tested.” That is what NAFDAC Food Safety and Applied Nutrition (FSAN) and Post-Marketing Surveillance (PMS) are doing this week at the production facilities and in the market. The public will be duly updated with the outcomes of the investigation.”

According to earlier research, eating bread, rice, and noodles frequently raises your risk of developing chronic illnesses like cancer, diabetes, hypertension, kidney damage, stroke, and obesity.

In recent years, there have been both proponents and opponents of the idea that eating foods with a high glycemic index, potassium bromate, and arsenic over an extended period of time increases the risk of developing non-communicable diseases.

Additionally, SWIPHA announced yesterday the recall of all batches of Polyfort Suspension due to a downward trend.

Constipation, heartburn, and excessive acidity can all be treated with Polyfort Suspension.

Kindly be informed that we are launching an immediate recall for all batches of Polyfort Suspension in stock, SWIPHA wrote in a letter titled “Recall Exercise for Ployfort Suspension” and sent to its distributors and clients on April 27, 2023.

“This is on account of the result of the ongoing stability study on batches LS222072, LS222073, and LS222074, showing a negative trend. We are currently carrying out further investigations on other batches.

“However, we are mandated to inform you within 24 to 48 hours. We are unable to wait for the outcome of this investigation, hence, the decision to recall all batches of Polyfort in your custody.”

The letter continued, “Further sales of Polyfort Suspension in your possession should cease, and inventory should be separated right away. Also, contact customers to whom you sold Polyfort suspension to return them back to you. All Polyfort stock (your stock and that of your customers) should be handed over to the Swipha medical or sales representatives assigned to you.”